# CATNON (EORTC 26053-22054)

Source: https://onco.cc/trials/catnon/  
OnCo record `catnon` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CATNON showed that a year of temozolomide after radiotherapy lengthens survival in anaplastic gliomas that lack the 1p/19q co-deletion, and that the benefit is concentrated in IDH-mutant tumours.

## Summary

CATNON randomised 751 adults with newly diagnosed 1p/19q non-co-deleted anaplastic glioma in a two-by-two design to radiotherapy alone, with concurrent temozolomide, with 12 cycles of adjuvant temozolomide, or both. Adjuvant temozolomide improved overall survival (hazard ratio 0.65 in the interim analysis; five-year survival 55.9 vs 44.1 percent), while concurrent temozolomide did not in the tumours as a whole and helped only IDH-mutant tumours (van den Bent and colleagues, Lancet 2017 and Lancet Oncology 2021).

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-16
- Tags: radiation-wave2
- Registry id: NCT00626990
- Phase: 3
- Setting: Newly diagnosed anaplastic glioma without 1p/19q co-deletion: radiotherapy with or without concurrent and with or without adjuvant temozolomide
- Sponsor: EORTC
- Enrolled: 751
- Result: Adjuvant temozolomide: overall survival hazard ratio 0.65; 5-year survival 55.9% vs 44.1%. Concurrent temozolomide benefit confined to IDH-mutant tumours.

## Sources

- ClinicalTrials.gov NCT00626990: https://clinicaltrials.gov/study/NCT00626990
- Lancet 2017: https://doi.org/10.1016/S0140-6736(17)31442-3

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- terms: [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/)

---
JSON: https://onco.cc/api/v1/entities/catnon.json